New combo therapy shows promise for rare blood cancer
NCT ID NCT07206264
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new treatment for mantle cell lymphoma, a rare blood cancer. It combines chemotherapy with targeted drugs to see if it can keep the cancer from coming back. The study involves 45 people who have not been treated before, and uses scans and blood tests to guide therapy.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MANTLE CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fujian Provincial Cancer Hospital
Fuzhou, Fujian, China
-
Harbin Medical University Cancer Hospital
Harbin, Heilongjiang, China
-
Hebei Medical University Tumor Hospital
Shijiazhuang, Hebei, China
-
Shandong Cancer Hospital
Jinan, Shandong, China
-
Tianjin Medical University Cancer Institute and Hospital
Tianjin, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A shot at safer CAR t: early brain protection for lymphoma patients?
- Engineered immune cells take aim at Hard-to-Treat lymphomas
- Can donor immune cells be engineered to fight blood cancer?
- Can a cancer drug reboot the immune system after a stem cell transplant?
- Can a targeted drug boost standard chemo for a rare blood cancer?
- Smartwatches track hidden heart risk in blood cancer patients